Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Annals of OncologyPublished 24 February 2006Open access
Mitch Dowsett, J. Houghton, Cecilie Riis Iden, Janine Salter, J R Farndon, Roger A’Hern
Citations268
SJR quartileQ1
SJR score19.07
SNIP10.48
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamxifen therapy on the basis of ER status alone, consistent with HER2 positive tumours being resistant to tamoxIFen.
Abstract
Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamoxifen therapy on the basis of ER status alone. The data are consistent with HER2 positive tumours being resistant to tamoxifen.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
The LancetEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
7,563 Citations2005
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
JNCI Journal of the National Cancer InstituteTamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5,508 Citations1998Bernard Fisher, Joseph P. Costantino +15 more
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
The LancetTamoxifen for early breast cancer: an overview of the randomised trials
4,105 Citations1998Early Breast Cancer Tr.group, -, Klijn, Jan
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
Journal of Clinical OncologyEstrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
2,063 Citations1999Jennet Harvey, Gary M. Clark +2 more
IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
Annals of OncologyMeeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
1,130 Citations2005Aron Goldhirsch, John H. Glick +4 more
The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer, reaffirming that the first consideration was endocrine responsiveness.
Journal of Clinical OncologyAmerican Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
1,034 Citations2004Eric P. Winer, Clifford A. Hudis +20 more
It is believed that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen.
Journal of Biological ChemistryEstrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.
798 Citations1978Kathryn B. Horwitz, William McGuire
MCF-7 cells of human breast cancer origin responded to estradiol (E) treatment with increased levels of progesterone receptor (PgR) showing that human breast cells which have undergone malignant changes can continue to synthesize a specific protein under hormone control.
Journal of Clinical OncologyProgesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases
757 Citations2003Valérie‐Jeanne Bardou, Grazia Arpino +3 more
When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy and should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients.
The LancetEPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER
497 Citations1985J R C Sainsbury, Gajanan V. Sherbet +2 more
The results suggest that the presence of EGF receptors is associated with metastatic potential and that the growth of a proportion of poor-prognosis oestrogen-receptor-negative tumours may be regulated by peptide growth factors interacting with the EGF receptor.
PubMedSensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
483 Citations1994Michael F. Press, Giun‐Yi Hung +2 more
The ability of these antibodies to detect overeexpression was extremely variable, providing an important explantation for the variable overexpression rate reported in the literature.
British Journal of CancerRelationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
380 Citations1992C Wright, S Nicholson +6 more
It is suggested that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.
PubMedInduction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.
343 Citations1992A Butta, KA MacLennan +8 more
In vivo evidence is found that 3 months of tamoxifen treatment causes a consistent induction of extracellular TGF-beta 1 in breast cancer biopsies, compared with matched pretreatment samples from the same patient.
Journal of Clinical OncologyElevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
300 Citations1995Kim Leitzel, Y A Teramoto +7 more
Patients with ER+/c-erbB-2+ metastatic breast cancer are less likely to respond to hormone treatment than ER-/progesterone receptor-positive (PR+) patients and their survival duration is shorter.
Journal of Clinical OncologyRetrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study
264 Citations2005Mitch Dowsett, Jack Cuzick +4 more
Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER-/Pg R- subgroups, but the benefit was substantially greater in the PgR- subgroup.
Molecular EndocrinologyMINIREVIEW: Estrogen Receptor Variants in Clinical Breast Cancer
262 Citations1991William McGuire, Gary C. Chamness +1 more
Using a yeast transactivation assay, the screening techniques of chemical mismatch cleavage, single stranded conformational polymorphism, and gel retardation are used to discover a number of estrogen receptor RNA variants in clinical breast cancer tissues that could have clinical significance, helping to explain breast tumor behavior and patient outcome.
British Journal of CancerControlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
250 Citations1988Analysis at Eight Years by 'Nolvadex'
At a maximum follow up of 8 years in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxIFen daily for 2 years.
Journal of Clinical OncologyPrediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
240 Citations1997Hideko Yamauchi, A. O’Neill +5 more
Pretreatment circulating NRP levels predict a low likelihood of benefit from HT, specifically DRO, in patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancer, even when adjusted for other known predictive factors.
PubMedExpression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
192 Citations1997Jacqueline C. Newby, Stephen Johnston +2 more
At the time of disease progression compared to pretreatment, there was no significant change in expression of either receptor, irrespective of initial response, and the inverse relationship between EGFR and estrogen receptor was maintained at relapse on tamoxifen.
European Journal of CancerRelationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
181 Citations1993Robert I. Nicholson, R A McClelland +7 more
Data confirm the prognostic importance of EGF-R measurements in breast cancer and may infer a functional interaction between this protein and the c-erbB-2 protein product in the aberrant growth of a subset of breast tumours.
GeneOncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
175 Citations1995Els M.J.J. Berns, John A. Foekens +5 more
The potential of oncogene amplifications as markers for the prediction of (i) (relapse-free) survival, (ii) response to first-line endocrine therapy and (iii) subsequent chemotherapy in patients with recurrent breast cancer is clarified.
Journal of Steroid BiochemistryEpidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
168 Citations1989Adrian L. Harris, S Nicholson +4 more
Epidermal growth factor receptors (EGFRs) were measured in 221 primary breast cancers by ligand binding with 125I-labelled EGF, and high-affinity sites were quantitated, and expression of neu conferred similar poor prognosis to EGFR expression in all prognostic subgroups.
Clinical Cancer ResearchCan Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?
140 Citations2005Sian Tovey, Barbara Dunne +4 more
It is shown that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxIFen treatment.
Elsevier eBooksSteroid Hormone Receptors in Breast Cancer Treatment Strategy
133 Citations1980William McGuire
The chapter highlights the information that estrogen receptor (ER) provides in the primary tumor and presents some innovative uses of combined endocrine chemotherapy.
PubMedExon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
106 Citations1995A A Daffada, S R Johnston +4 more
Elevated delta 5 ER mRNA levels may be important in some tumors, especially those which continue to express high levels of PgR/pS2, which is unlikely to be responsible for tamoxifen resistance in most breast cancers.
British Journal of CancerCyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer
103 Citations1988Preliminary Analysis by the CRC Adjuvant Breast Trial Working Party
Results from this study closely parallel the two trials it set out to repeat and preliminary analyses demonstrate a significant improvement in event-free survival for both regimens.
CancerThe prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer
101 Citations1988J. Alexieva-Figusch, Wim L.J. van Putten +3 more
It is concluded that the PgR level of the primary tumor is a better prognosticator than the ER level and that ER offered no additional ability for discriminating between low‐ and high‐risk patients once Pg R was included in the model.
Biochemical PharmacologyVariation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; Correlations with cytotoxicity
80 Citations1990Martin Rowlands, Iris B. Parr +3 more
The results are consistent with the possibility that calmodulin is important to the functioning of oestrogen receptor mediated growth in MCF-7 cells.
Journal of Clinical PathologyComparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.
79 Citations1994Gloria Saccani Jotti, S. Johnston +3 more
The concordance between the classic enzyme immunoassay technique and the new immunohistochemical method on paraffin wax embedded sections was good and may allow oestrogen receptor content to be determined in large cohorts of patients in whom archival tumour material is available.
International Journal of CancerRat monoclonal antibodies to the external domain of the product of the C‐<i>erb</i>B‐2 proto‐oncogene
44 Citations1990Jennifer M. Styles, S. Harrison +2 more
Four rat monoclonal antibodies have been prepared against the external domain of the product of the c‐erbB‐2 proto‐oncogene and should be useful not only for immunocytochemical diagnoses but also for radio‐immunoscintigraphic and therapeutic applications.
International Journal of CancerTime-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts
43 Citations1999Simone Detre, Janine Salter +7 more
The results provide a framework for the use of certain proliferation‐ and cell death‐related biological parameters after hormone withdrawal from estrogen‐dependent MCF‐7 xenografts in athymic nude mice using immunohistochemical techniques in comparisons of hormonal agents for human breast cancer treatment.
Annals of Surgical OncologyTamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired cohort study
34 Citations1998Gay‐Hui Ho, Chenyang Ji +4 more
These significant alterations in serum concentrations of IGFs and BPs with tamoxifen therapy suggest that the IGF system is a potential mechanism by which tamoxIFen exerts its growth inhibitory effect on breast carcinomas.
British Journal of CancerImmunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer
33 Citations1995JC Newby, Roger A’Hern +4 more
In this exploratory study on a limited tumour set, EGFR was a significant adverse prognostic factor for both relapse-free survival and overall survival when measured by this immunohistochemical assay, but was not significant when measure by ligand-binding assay.
The LancetAdjuvant aromatase inhibitors for breast cancer
33 Citations2005Anthony Howell
A combined analysis of data from two prospective, multicentre, randomised, open-label trials with nearly identical inclusion criteria lends support to a switch from tamoxifen to anastrozole in patients who have completed 2 years' adjuvant tamoxIFen.
Biochemical PharmacologyInhibitory effect of the antioxidant ethoxyquin on electron transport in the mitochondrial respiratory chain
26 Citations1995JoséL. Reyes, M.Elisabeth Hernández +2 more
The direct inhibitory effect of EQ on NADH dehydrogenase was a most relevant finding, since no inhibitor for the partial reaction of NADH-ferricyanide on this complex has been reported previously.
Biochemical and Biophysical Research CommunicationsModes of inhibition of protein kinase C by triphenylacrylonitrile antiestrogens
24 Citations1989Eric Bignon, Kouji Ogita +5 more
Evidence suggests that PKC activity can be inhibited by different routes depending on the TPE structure: diethylaminoethoxy side chain-substituted TPEs interact with PS as well as with the regulatory domain, whereas the trihydroxylated derivative inhibits the enzyme by interacting with the catalytically active site.
OncologyEffects of Cytotoxic Chemotherapy on Ovarian and Adrenal Steroidogenesis in Pre-Menopausal Breast Cancer Patients
22 Citations2009Mitch Dowsett, J. Richner
Although an endocrine response by the tumour might be expected to cytotoxic-induced ovarian ablation, the clinical significance of the disrupted, but incompletely suppressed ovarian function is unknown.
Journal of Clinical OncologyTamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)—The German Adjuvant Breast Cancer Group
17 Citations2005Manfred Kaufmann, Erika Graf +9 more
This study contributes substantially to finalization of the presently emerging evidence that tamoxifen does not benefit women with receptor-negative breast cancer after chemotherapy.